Experts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted the adoption of biosimilars.
The coronavirus pandemic was front and centre of everyone’s minds at this year’s spring eyeforpharma conferences – not least because the usual locations of Barcelona and Philadelphia had been swapp
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, government and commercial payers are scrutinising the economic value of new treatments more
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
